You are here:Home-Inhibitors & Agonists-NF-κB Pathway-TAK1

Request The Product List ofTAK1 TAK1

Cat. No. Product Name CAS No. Information
PC-61199

PF-05381941

1474022-02-0

PF-05381941 (PF 05381941, PF05381941) is a potent, dual TAK1/p38a inhibitor with IC50 of 156/186 nM respectively, with good kinome selectivity against 50 representative kinases; inhibits LPS-stimulated release of TNF-α from human peripheral mononuclear cells with IC50 of 8 nM.

PC-61197

Takinib

1111556-37-6

Takinib is a potent, selective TAK1 inhibitor with IC50 of 9.5 nM, selectively induces apoptosis following TNF-a stimulation; weakly inhibits IRAK4, IRAK1, GCK, CLK2, and MINK1 with IC50 of 120-430 nM against the MRC Dundee kinase panel, does not inhibit any of the MAP2Ks or MAP3Ks family members; inhibits phosphorylation of IKK, MAPK 8/9, and c-Jun, induces apoptosis in RA fibroblast-like synoviocytes and reduces IL-6 secretion, induces TNF-α-dependent cell death in rheumatoid arthritis and breast cancer cells.

PC-62868

(5Z)-7-Oxozeaenol

66018-38-0 (5Z)-7-Oxozeaenol is a potent and selective TAK1 inhibitor with IC50 of 8 nM, displays >33-fold and >62-fold selectivity over MEKK1 and MEKK4 respectively; inhibits IL-1-induced activation of NF-κB (IC50 = 83 nM) and JNK/p38; also inhibits production of inflammatory mediators, and sensitizes cells to TRAIL- and TNF-α-induced apoptosis in vitro.
PC-62810

TAK1-IN-1

1356013-39-2 TAK1-IN-1 is a potent, selective, Type I (ATP-competitive, DFG-in) TAK1 inhibitor with Kd of 59 nM, a thienopyrimidine scaffold that serves as a good starting point for medicinal chemistry.
PC-61198

5Z-7-Oxozeaenol

253863-19-3 A potent, selective TAK1 inhibitor with IC50 of 8 nM, displays >33-fold and >62-fold selectivity over MEKK1 and MEKK4 respectively; inhibits IL-1-induced activation of NF-κB (IC50= 83 nM) and JNK/p38, inhibits production of inflammatory mediators, and sensitizes cells to TRAIL- and TNF-α-induced apoptosis in vitro; significantly enhances chemotherapeutic efficacy in vivo.
PC-70029

Minnelide

1254702-87-8 A water-soluble prodrug of triptolide that is highly effective in reducing pancreatic tumor growth and spread, and improving survival; efficiently downregulates both CD133(-) and CD133(+) population in the tumors, resulting in a 60% decrease in tumor volume; also is very effective as a therapeutic option against Castration Resistant Prostate Cancer (CRPC).

Pancreatic Cancer

Phase 2

PC-45814

Triptolide

38748-32-2 The active diterpene in the traditional Chinese medicine Lei Gong Teng, induces Ca(2+) release by a polycystin-2 (PC2)-dependent mechanism; arrests cellular proliferation and attenuates overall cyst formation by restoring Ca(2+) signaling in a murine model of ADPKD; also covalently binds to human XPB (ERCC3), a subunit of the transcription factor TFIIH, and inhibits its DNA-dependent ATPase activity, which leads to the inhibition of RNA polymerase II-mediated transcription; inhibits TAK1 kinase activity by interfering with the formation of the TAK1-TAB1 complex in macrophages.

Pancreatic Cancer

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com